全文获取类型
收费全文 | 3163篇 |
免费 | 177篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 134篇 |
妇产科学 | 49篇 |
基础医学 | 306篇 |
口腔科学 | 89篇 |
临床医学 | 299篇 |
内科学 | 598篇 |
皮肤病学 | 114篇 |
神经病学 | 217篇 |
特种医学 | 74篇 |
外科学 | 585篇 |
综合类 | 69篇 |
一般理论 | 4篇 |
预防医学 | 217篇 |
眼科学 | 151篇 |
药学 | 186篇 |
中国医学 | 13篇 |
肿瘤学 | 214篇 |
出版年
2023年 | 25篇 |
2022年 | 30篇 |
2021年 | 97篇 |
2020年 | 69篇 |
2019年 | 114篇 |
2018年 | 126篇 |
2017年 | 92篇 |
2016年 | 112篇 |
2015年 | 122篇 |
2014年 | 161篇 |
2013年 | 185篇 |
2012年 | 232篇 |
2011年 | 256篇 |
2010年 | 143篇 |
2009年 | 114篇 |
2008年 | 162篇 |
2007年 | 156篇 |
2006年 | 161篇 |
2005年 | 128篇 |
2004年 | 146篇 |
2003年 | 120篇 |
2002年 | 124篇 |
2001年 | 28篇 |
2000年 | 27篇 |
1999年 | 27篇 |
1998年 | 16篇 |
1997年 | 14篇 |
1996年 | 12篇 |
1995年 | 19篇 |
1994年 | 22篇 |
1993年 | 14篇 |
1992年 | 29篇 |
1991年 | 21篇 |
1990年 | 16篇 |
1989年 | 23篇 |
1988年 | 23篇 |
1987年 | 17篇 |
1986年 | 16篇 |
1985年 | 19篇 |
1984年 | 20篇 |
1983年 | 12篇 |
1982年 | 8篇 |
1981年 | 9篇 |
1980年 | 10篇 |
1979年 | 7篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1976年 | 7篇 |
1971年 | 6篇 |
1931年 | 7篇 |
排序方式: 共有3351条查询结果,搜索用时 31 毫秒
1.
2.
Uday Yanamandra Prateek Deo Kamal Kant Sahu Ram Vasudevan Nampoothiri Nalini Gupta Anusree Prabhakaran Deb Prasad Dhibhar Alka Khadwal Gaurav Prakash Man Upadesh Singh Sachdeva Deepesh Lad Neelam Varma Subhash Varma Pankaj Malhotra 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):183-189.e1
Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献3.
4.
5.
6.
7.
8.
9.
10.
The US Food and Drug Administration granted acalabrutinib approval as the second Bruton tyrosine kinase (BTK) inhibitor to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma as monotherapy or in combination with obinutuzumab. This approval was based on 2 phase 3 trials: ELEVATE-TN and ASCEND. There are several concerns with the design of these trials, including suboptimal treatment of patients in the control arm, expansion of the trial population, and lack of data regarding efficacy or tolerability compared with ibrutinib, a first-in-class drug. The Food and Drug Administration approval of acalabrutinib for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma represents concerning drug approval patterns in the United States and a weakness in evidence generation. 相似文献